Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of FENM in healthy volunteers
NCT05921929Phase 1Withdrawn
- Sponsor
- ReST Therapeutics
- Start
- May 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluoroethylnormemantine in post-traumatic stress disorder (PTSD), Alzheimer's disease (AD) and major depressive disorder (MDD), sponsored by ReST Therapeutics. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 2 weeks. Planned start May 2024; status: withdrawn.
02
Drugs
fluoroethylnormemantine
03
Conditions
post-traumatic stress disorder (PTSD)Alzheimer's disease (AD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05921929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921929.